← Back to All US Stocks

ARTV Stock Analysis - Artiva Biotherapeutics, Inc. AI Rating

ARTV Nasdaq Biological Products, (No Diagnostic Substances) DE CIK: 0001817241
Analysis Date: Mar 20, 2026 | Data as of: 2025-12-31
AI Rating
STRONG SELL
92% Confidence

Investment Thesis

Artiva Biotherapeutics is a pre-revenue clinical-stage biopharmaceutical company burning significant cash with no approved products or revenue generation. The company is consuming approximately $80M annually in free cash flow with only $26.7M in cash reserves, indicating a critical runway issue within 4-6 months without additional financing.

ARTV Strengths

  • + Strong balance sheet with minimal debt ($0M long-term debt) and debt-free capital structure
  • + Adequate liquidity position currently with 8.61x current ratio despite cash burn
  • + Recent insider activity with 7 Form 4 filings suggesting active leadership engagement

ARTV Risks

  • ! Zero revenue with 100% YoY revenue decline - no commercial progress or approved products
  • ! Severe cash burn of $76.8M in operating cash flow and $79.3M negative free cash flow annually
  • ! Critical cash runway crisis - only $26.7M cash reserves against $79.3M annual burn rate creates existential dilution risk within months
  • ! Massive shareholder value destruction with -76.3% ROE and -64.0% ROA
  • ! Operating losses of $89.8M indicate no clear path to profitability or commercialization success

Key Metrics to Watch

ARTV Financial Metrics

Revenue
$0.0
Net Income
$-83.9M
EPS (Diluted)
$-3.43
Free Cash Flow
$-79.3M
Total Assets
$130.9M
Cash Position
$26.7M

ARTV Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE -76.3%
ROA -64.0%
FCF Margin N/A

ARTV Balance Sheet & Liquidity

Current Ratio
8.61x
Quick Ratio
8.61x
Debt/Equity
0.00x
Debt/Assets
16.0%
Interest Coverage
N/A
Long-term Debt
N/A

ARTV 5-Year Financial Trend

ARTV 5-year financial data: Year 2024: Revenue $32.9M, Net Income -$28.7M, EPS $-35.78.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Artiva Biotherapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-5.81 indicates the company is currently unprofitable.

ARTV Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

ARTV Quarterly Performance

Quarterly financial performance data for Artiva Biotherapeutics, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2024 $26.7M $11.3M $-0.92
Q2 2024 $3.5M -$11.3M $-14.09

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

ARTV Capital Allocation

Operating Cash Flow
-$76.8M
Cash generated from operations
Capital Expenditures
$2.6M
Investment in assets
Dividends
None
No dividend program

ARTV SEC Filings

Access official SEC EDGAR filings for Artiva Biotherapeutics, Inc. (CIK: 0001817241)

📄 10-K Annual Reports 📋 10-Q Quarterly Reports 📰 8-K Current Reports 📊 Proxy Statements 🔍 All Filings

Related Stock Analysis

ARMP
Armata Pharmaceuticals, Inc.
STRONG SELL
ARGX
ARGENX SE
HOLD
APTOF
Aptose Biosciences Inc.
STRONG SELL
ASPI
ASP Isotopes Inc.
STRONG SELL
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 20, 2026 | Data as of: 2025-12-31 | Powered by Claude AI